Clinical trial of RNF180/Setpin9 Gene methylation Detection Kit (PCR fluorescent probe method)

Validation of the RNF180/Septin9 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant gastric disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049352

Enrollment

Unknown

Registered

2021-07-31

Start date

2017-03-10

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Gold Standard:The results were compared with the results of gastroscopy and/or pathology in the diagnosis of gastric cancer. The coincidence rate of the test kit in clinical application was evaluated

Index test:RNF180&#32

Gene,&#32

Septin9&#32

Gene&#32

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Complete sample information, including sample medical record number, gender, age, clinical diagnosis information;No gastric cancer surgery history, and no radiotherapy and chemotherapy; The woman should not be pregnant; To complete the whole process of clinical screening; Sign the informed consent form.

Exclusion criteria

Exclusion criteria: A hemolysis sample; Any other circumstances under which the investigator considers it inappropriate to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Methylation of the Septin9 gene;Methylation of the RNF180 gene;	—

Countries

China

Contacts

Public ContactXiaoliang Han

Biochain(Beijing) Technology Co., LTD

sean.han@biochainbj.com+86 18612824530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026